Produktinformation
AZP-531 is a drug that has been shown to have pharmacokinetic properties and pharmacodynamics in humans. It has a terminal half-life of about 7 hours, which is shorter than the half-life of most drugs. AZP-531 binds to the myocardium and mesentery and can be used to treat metabolic disorders such as obesity. This drug has also been shown to inhibit protein synthesis in animals, but not humans. The drug was well-tolerated by healthy volunteers with no serious adverse effects reported. AZP-531 is an analog of rapamycin, a macrolide antibiotic that was originally developed for cancer therapy but was found ineffective for this purpose. Rapamycin inhibits cell growth by binding to the immunophilin FKBP12, which prevents the mTOR kinase from associating with its substrate S6K1 and phosphorylating it. AZP-531 may have potential as an anti-cancer agent
Chemische Eigenschaften
Technische Anfrage zu: 3D-NTB54362 AZP-531
Wenn Sie ein Angebot anfordern oder eine Bestellung aufgeben möchten, legen Sie stattdessen die gewünschten Produkte in Ihren Warenkorb und fordern Sie dann ein Angebot oder eine Bestellung an aus dem Warenkorb. Es ist schneller, billiger und Sie können von den verfügbaren Rabatten und anderen Vorteilen profitieren.
